Indoleamine-2,3-dioxygenase, an immunosuppressive enzyme that inhibits natural killer cell function, as a useful target for ovarian cancer therapy

International Journal of Oncology

Volumn 40, Issue 4, 2012, Pages 929-934

  Wang, Dongdong ^a,b   Saga, Yasushi ^a   Mizukami, Hiroaki ^a   Sato, Naoto ^a   Nonaka, Hiroaki ^a   Fujiwara, Hiroyuki ^a   Takei, Yuji ^a   Machida, Shizuo ^a   Takikawa, Osamu ^c   Ozawa, Keiya ^a   Suzuki, Mitsuaki ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b CHINA MEDICAL UNIVERSITY   (China)

^c NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY   (Japan)

Author keywords

Indoleamine 2,3 dioxygenase; Natural killer cell; Ovarian cancer; Peritoneal dissemination; Short hairpin RNA

Indexed keywords

INDOLEAMINE 2,3 DIOXYGENASE; SHORT HAIRPIN RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; IN VIVO STUDY; MOUSE; NATURAL KILLER CELL; NONHUMAN; OVARY CANCER; PERITONEUM METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA VECTOR; SYSTEMATIC REVIEW;

ANIMALS; CELL LINE, TUMOR; DISEASE PROGRESSION; DOWN-REGULATION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; KILLER CELLS, NATURAL; MICE; MICE, INBRED BALB C; MICE, NUDE; OVARIAN NEOPLASMS; RNA, SMALL INTERFERING; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84863354166     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.1295     Document Type: Article

References (40)

1. Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin 60: 277-300, 2010.
2. Heintz AP: Surgery in advanced ovarian carcinoma: is there proof to show the benefit? Eur J Surg Oncol 14: 91-99, 1988.
3. McGuire WP, Hoskins WJ, Brady MF, et al: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334: 1-6, 1996. (Pubitemid 26012496)
4. Takei Y, Suzuki M, Ohwada M, et al: A feasibility study of paclitaxel and carboplatin therapy in Japanese patients with epithelial ovarian cancer. Oncol Rep 10: 951-955, 2003.
5. Dunn GP, Bruce AT, Ikeda H, Old LJ and Schreiber RD: Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3: 991-998, 2002. (Pubitemid 35363648)
6. Schreiber RD, Old LJ and Smyth MJ: Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 331: 1565-1570, 2011.
7. Higuchi K and Hayaishi O: Enzymic formation of D-kynurenine from D-tryptophan. Arch Biochem Biophys 120: 397-403, 1967.
8. Yamamoto S and Hayaishi O: Tryptophan pyrrolase of rabbit intestine. D- and L-tryptophan-cleaving enzyme or enzymes. J Biol Chem 242: 5260-5266, 1967.
9. Shimizu T, Nomiyama S, Hirata F and Hayaishi O: Indoleamine 2,3-dioxygenase. Purification and some properties. J Biol Chem 253: 4700-4706, 1978. (Pubitemid 8372084)
10. Yoshida R, Urade Y, Tokuda M and Hayaishi O: Induction of indoleamine 2,3-dioxygenase in mouse lung during virus infection. Proc Natl Acad Sci USA 76: 4084-4086, 1979. (Pubitemid 9249028)
11. Yoshida R and Hayaishi O: Induction of pulmonary indoleamine 2,3-dioxygenase by intraperitoneal injection of bacterial lipopolysaccharide. Proc Natl Acad Sci USA 75: 3998-4000, 1978. (Pubitemid 8399859)
12. Fujigaki S, Saito K, Sekikawa K, et al: Lipopolysaccharide induction of indoleamine 2,3-dioxygenase is mediated dominantly by an IFN-gamma-independent mechanism. Eur J Immunol 31: 2313-2318, 2001. (Pubitemid 32785349)
13. Munn DH, Zhou M, Attwood JT, et al: Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 281: 1191-1193, 1998. (Pubitemid 28406294)
14. Schroecksnadel K, Winkler C, Duftner C, Wirleitner B, Schirmer M and Fuchs D: Tryptophan degradation increases with stage in patients with rheumatoid arthritis. Clin Rheumatol 25: 334-337, 2006.
15. Brown RR, Ozaki Y, Datta SP, Borden EC, Sondel PM and Malone DG: Implications of interferon-induced tryptophan catabolism in cancer, auto-immune diseases and AIDS. Adv Exp Med Biol 294: 425-435, 1991.
16. Labadarios D, McKenzie DY, Dickerson JW and Parke DV: Metabolic abnormalities of tryptophan and nicotinic acid in patients with rheumatoid arthritis. Rheumatol Rehabil 17: 227-232, 1978. (Pubitemid 9061301)
17. Varga J, Yufit T and Brown RR: Inhibition of collagenase and stromelysin gene expression by interferon-gamma in human dermal fibroblasts is mediated in part via induction of tryptophan degradation. J Clin Invest 96: 475-481, 1995.
18. Mellor AL and Munn DH: IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol 4: 762-774, 2004. (Pubitemid 39336293)
19. Uyttenhove C, Pilotte L, Theate I, et al: Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 9: 1269-1274, 2003. (Pubitemid 37279849)
20. Vivier E, Tomasello E, Baratin M, Walzer T and Ugolini S: Functions of natural killer cells. Nat Immunol 9: 503-510, 2008. (Pubitemid 351560519)
21. Lanier LL: Up on the tightrope: natural killer cell activation and inhibition. Nat Immunol 9: 495-502, 2008.
22. Della Chiesa D, Carlomagno S, Frumento G, et al: The tryptophan catabolite L-kynurenine inhibits the surface expression of NKp46- and NKG2D-activating receptors and regulates NK-cell function. Blood 108: 4118-4125, 2006. (Pubitemid 44913283)
23. Inaba T, Ino K, Kajiyama H, et al: Indoleamine 2,3-dioxygenase expression predicts impaired survival of invasive cervical cancer patients treated with radical hysterectomy. Gynecol Oncol 117: 423-428, 2010.
24. Ino K, Yoshida N, Kajiyama H, et al: Indoleamine 2,3-dioxygenase is a novel prognostic indicator for endometrial cancer. Br J Cancer 95: 1555-1561, 2006. (Pubitemid 44863359)
25. Takao M, Okamoto A, Nikaido T, et al: Increased synthesis of indoleamine-2,3-dioxygenase protein is positively associated with impaired survival in patients with serous-type, but not with other types of, ovarian cancer. Oncol Rep 17: 1333-1339, 2007.
26. Inaba T, Ino K, Kajiyama H, et al: Role of the immunosuppressive enzyme indoleamine 2,3-dioxygenase in the progression of ovarian carcinoma. Gynecol Oncol 115: 185-192, 2009.
27. Gartel AL and Kandel ES: RNA interference in cancer. Biomol Eng 23: 17-34, 2006. (Pubitemid 43243836)
28. Scherr M and Eder M: Gene silencing by small regulatory RNAs in mammalian cells. Cell Cycle 6: 444-449, 2007. (Pubitemid 46393448)
29. Hannon GJ, Chubb A, Maroney PA, Hannon G, Altman S and Nilsen TW: Multiple cis-acting elements are required for RNA polymerase III transcription of the gene encoding H1 RNA, the RNA component of human RNase P. J Biol Chem 266: 22796-22799, 1991. (Pubitemid 21908720)
30. Walchli S and Sioud M: Vector-based delivery of siRNAs: in vitro and in vivo challenges. Front Biosci 13: 3488-3493, 2008. (Pubitemid 351594698)
31. Fogh J, Wright WC and Loveless JD: Absence of HeLa cell contamination in 169 cell lines derived from human tumors. J Natl Cancer Inst 58: 209-214, 1977. (Pubitemid 8042505)
32. Yagita M, Huang CL, Umehara H, et al: A novel natural killer cell line (KHYG-1) from a patient with aggressive natural killer cell leukemia carrying a p53 point mutation. Leukemia 14: 922-930, 2000. (Pubitemid 30235072)
33. Takikawa O, Kuroiwa T, Yamazaki F and Kido R: Mechanism of interferon-gamma action. Characterization of indoleamine 2,3-dioxygenase in cultured human cells induced by interferon-gamma and evaluation of the enzyme-mediated tryptophan degradation in its anticellular activity. J Biol Chem 263: 2041-2048, 1988. (Pubitemid 18052167)
34. Miyagishi M and Taira K: Strategies for generation of an siRNA expression library directed against the human genome. Oligonucleotides 13: 325-333, 2003. (Pubitemid 38404817)
35. Nonaka H, Saga Y, Fujiwara H, et al: Indoleamine 2,3-dioxygenase promotes peritoneal dissemination of ovarian cancer through inhibition of natural killer cell function and angiogenesis promotion. Int J Oncol 38: 113-120, 2011.
36. Cady SG and Sono M: 1-Methyl-DL-tryptophan, beta-(3-benzofuranyl)-DL- alanine (the oxygen analog of tryptophan), and beta-[3-benzo(b)thienyl]-DL- alanine (the sulfur analog of tryptophan) are competitive inhibitors for indoleamine 2,3-dioxygenase. Arch Biochem Biophys 291: 326-333, 1991.
37. Muller AJ, DuHadaway JB, Donover PS, Sutanto-Ward E and Prendergast GC: Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat Med 11: 312-319, 2005. (Pubitemid 40460560)
38. Yen MC, Lin CC, Chen YL, et al: A novel cancer therapy by skin delivery of indoleamine 2,3-dioxygenase siRNA. Clin Cancer Res 15: 641-649, 2009.
39. Shiota M, Ikeda Y and Wadhwa R: The factors that contribute to the long-term expression of siRNA. Nucleic Acids Symp Ser (Oxf) 2006: 243-244, 2006.
40. Serda RE, Godin B, Blanco E, Chiappini C and Ferrari M: Multi-stage delivery nano-particle systems for therapeutic applications. Biochim Biophys Acta 1810: 317-329, 2011.